Personnel Announcement
Novo Nordisk Pharma announces the appointment of the Head of Healthcare Policy and Public Affairs, effective March 1, 2026.
Novo Nordisk Pharma Ltd. (President: Keisuke Kotani, Headquarters: Chiyoda-ku, Tokyo, hereinafter "Novo Nordisk Pharma") hereby announces the following personnel changes.
① Personnel Changes (Effective March 1, 2026)
Name | New Position | Former Position |
Ryo Kato | Head of Healthcare Policy and Public Affairs | Director, Public Affairs Department, Healthcare Policy and Public Affairs |
Name | New Position | Former Position |
Junko McMaster | Director, Corporate Affairs Department | - |
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built on our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk Pharma Ltd. was established in Japan in 1980. For more information, visit our website at www.novonordisk.co.jp